Recent advances in the pathophysiology of nephrolithiasis

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Over the past 10 years, major progress has been made in the pathogenesis of uric acid and calcium stones. These advances have led to our further understanding of a pathogenetic link between uric acid nephrolithiasis and the metabolic syndrome, the role of Oxalobacter formigenes in calcium oxalate stone formation, oxalate transport in Slc26a6-null mice, the potential pathogenetic role of Randall's plaque as a precursor for calcium oxalate nephrolithiasis, and the role of renal tubular crystal retention. With these advances, we may target the development of novel drugs including (1) insulin sensitizers; (2) probiotic therapy with O. formigenes, recombinant enzymes, or engineered bacteria; (3) treatments that involve the upregulation of intestinal luminal oxalate secretion by increasing anion transporter activity (Slc26a6), luminally active nonabsorbed agents, or oxalate binders; and (4) drugs that prevent the formation of Randall's plaque and/or renal tubular crystal adhesions.

Original languageEnglish (US)
Pages (from-to)585-595
Number of pages11
JournalKidney International
Volume75
Issue number6
DOIs
StatePublished - 2009

Fingerprint

Nephrolithiasis
Oxalobacter formigenes
Oxalates
Uric Acid
Kidney
Calcium Oxalate
Probiotics
Pharmaceutical Preparations
Anions
Up-Regulation
Insulin
Calcium
Bacteria
Enzymes
Therapeutics

Keywords

  • Calcium oxalate
  • Kidney stone
  • Metabolic syndrome
  • Nephrolithiasis
  • Uric acid

ASJC Scopus subject areas

  • Nephrology

Cite this

Recent advances in the pathophysiology of nephrolithiasis. / Sakhaee, Khashayar.

In: Kidney International, Vol. 75, No. 6, 2009, p. 585-595.

Research output: Contribution to journalArticle

@article{8ab31fa09a6242bc9ad7e97878d0e2fd,
title = "Recent advances in the pathophysiology of nephrolithiasis",
abstract = "Over the past 10 years, major progress has been made in the pathogenesis of uric acid and calcium stones. These advances have led to our further understanding of a pathogenetic link between uric acid nephrolithiasis and the metabolic syndrome, the role of Oxalobacter formigenes in calcium oxalate stone formation, oxalate transport in Slc26a6-null mice, the potential pathogenetic role of Randall's plaque as a precursor for calcium oxalate nephrolithiasis, and the role of renal tubular crystal retention. With these advances, we may target the development of novel drugs including (1) insulin sensitizers; (2) probiotic therapy with O. formigenes, recombinant enzymes, or engineered bacteria; (3) treatments that involve the upregulation of intestinal luminal oxalate secretion by increasing anion transporter activity (Slc26a6), luminally active nonabsorbed agents, or oxalate binders; and (4) drugs that prevent the formation of Randall's plaque and/or renal tubular crystal adhesions.",
keywords = "Calcium oxalate, Kidney stone, Metabolic syndrome, Nephrolithiasis, Uric acid",
author = "Khashayar Sakhaee",
year = "2009",
doi = "10.1038/ki.2008.626",
language = "English (US)",
volume = "75",
pages = "585--595",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Recent advances in the pathophysiology of nephrolithiasis

AU - Sakhaee, Khashayar

PY - 2009

Y1 - 2009

N2 - Over the past 10 years, major progress has been made in the pathogenesis of uric acid and calcium stones. These advances have led to our further understanding of a pathogenetic link between uric acid nephrolithiasis and the metabolic syndrome, the role of Oxalobacter formigenes in calcium oxalate stone formation, oxalate transport in Slc26a6-null mice, the potential pathogenetic role of Randall's plaque as a precursor for calcium oxalate nephrolithiasis, and the role of renal tubular crystal retention. With these advances, we may target the development of novel drugs including (1) insulin sensitizers; (2) probiotic therapy with O. formigenes, recombinant enzymes, or engineered bacteria; (3) treatments that involve the upregulation of intestinal luminal oxalate secretion by increasing anion transporter activity (Slc26a6), luminally active nonabsorbed agents, or oxalate binders; and (4) drugs that prevent the formation of Randall's plaque and/or renal tubular crystal adhesions.

AB - Over the past 10 years, major progress has been made in the pathogenesis of uric acid and calcium stones. These advances have led to our further understanding of a pathogenetic link between uric acid nephrolithiasis and the metabolic syndrome, the role of Oxalobacter formigenes in calcium oxalate stone formation, oxalate transport in Slc26a6-null mice, the potential pathogenetic role of Randall's plaque as a precursor for calcium oxalate nephrolithiasis, and the role of renal tubular crystal retention. With these advances, we may target the development of novel drugs including (1) insulin sensitizers; (2) probiotic therapy with O. formigenes, recombinant enzymes, or engineered bacteria; (3) treatments that involve the upregulation of intestinal luminal oxalate secretion by increasing anion transporter activity (Slc26a6), luminally active nonabsorbed agents, or oxalate binders; and (4) drugs that prevent the formation of Randall's plaque and/or renal tubular crystal adhesions.

KW - Calcium oxalate

KW - Kidney stone

KW - Metabolic syndrome

KW - Nephrolithiasis

KW - Uric acid

UR - http://www.scopus.com/inward/record.url?scp=61349110037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61349110037&partnerID=8YFLogxK

U2 - 10.1038/ki.2008.626

DO - 10.1038/ki.2008.626

M3 - Article

C2 - 19078968

AN - SCOPUS:61349110037

VL - 75

SP - 585

EP - 595

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 6

ER -